Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Get the detailed quarterly/annual income statement for Vivani Medical, Inc. (VANI). Find out the revenue, expenses and profit or loss over the last fiscal year.

ALAMEDA, Calif., November 13, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported ...

--Vivani Medical, Inc., a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal ...

Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight subjects.

Vivani Medical, Inc. VANI recently announced the filing of a Form 10 registration statement with the U.S. Securities and Exchange Commission (“SEC”), marking the first formal step toward ...

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical ...

Vivani Medical shares surged more than five-fold in early trading on Wednesday after the drug developer said its experimental under-the-skin drug implant helped reduce weight in obese mice in a ...

Vivani’s Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “We made significant progress advancing our proprietary GLP-1 implants for obesity and chronic weight management in the third ...

Vivani’s NPM-115 and NPM-119 are miniature, six-month, GLP-1 implants in development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively.